A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.
Though AML is a genetically heterogeneous disease, all its subtypes share a common feature: impaired differentiation of myeloid progenitor cells in the bone marrow. This differentiation block results in the accumulation of immature precursors of these cells within the bone…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply